Replacement therapy with growth hormone and pituitary tumor recurrence: the relevance of the problem.

M. Losa, E. Gatti, A. Rossini, R. Lanzi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Most cases of adult GH deficiency (AGHD) result from hypothalamic-pituitary tumors or their treatment. Some experimental and clinical observations suggest that GH may possess a mitogenic potential, thus raising the question of whether it is a safe treatment in patients with a previous pituitary tumor. Few study results have been reported on this topic. All of them have inevitable methodological flaws that limit their conclusions. However, all studies report that replacement therapy with GH does not seem to increase the risk of tumor progression or recurrence, when compared to historical or matched controls. Considering the slow-growing nature of most of these benign tumors and the absence of conclusive evidence from the available studies, a continuous imaging surveillance and longer follow-up periods are nevertheless mandatory for a definite statement on the safety of GH treatment in patients with previous pituitary tumors.

Original languageEnglish
Pages (from-to)75-78
Number of pages4
JournalJournal of Endocrinological Investigation
Volume31
Issue number9 Suppl
Publication statusPublished - Sep 2008

Fingerprint

Pituitary Neoplasms
Growth Hormone
Recurrence
Hypothalamic Neoplasms
Therapeutics
Neoplasms
Safety

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Replacement therapy with growth hormone and pituitary tumor recurrence : the relevance of the problem. / Losa, M.; Gatti, E.; Rossini, A.; Lanzi, R.

In: Journal of Endocrinological Investigation, Vol. 31, No. 9 Suppl, 09.2008, p. 75-78.

Research output: Contribution to journalArticle

@article{ccd7d295ade543f396c754ed5d1f1d2e,
title = "Replacement therapy with growth hormone and pituitary tumor recurrence: the relevance of the problem.",
abstract = "Most cases of adult GH deficiency (AGHD) result from hypothalamic-pituitary tumors or their treatment. Some experimental and clinical observations suggest that GH may possess a mitogenic potential, thus raising the question of whether it is a safe treatment in patients with a previous pituitary tumor. Few study results have been reported on this topic. All of them have inevitable methodological flaws that limit their conclusions. However, all studies report that replacement therapy with GH does not seem to increase the risk of tumor progression or recurrence, when compared to historical or matched controls. Considering the slow-growing nature of most of these benign tumors and the absence of conclusive evidence from the available studies, a continuous imaging surveillance and longer follow-up periods are nevertheless mandatory for a definite statement on the safety of GH treatment in patients with previous pituitary tumors.",
author = "M. Losa and E. Gatti and A. Rossini and R. Lanzi",
year = "2008",
month = "9",
language = "English",
volume = "31",
pages = "75--78",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Springer International Publishing",
number = "9 Suppl",

}

TY - JOUR

T1 - Replacement therapy with growth hormone and pituitary tumor recurrence

T2 - the relevance of the problem.

AU - Losa, M.

AU - Gatti, E.

AU - Rossini, A.

AU - Lanzi, R.

PY - 2008/9

Y1 - 2008/9

N2 - Most cases of adult GH deficiency (AGHD) result from hypothalamic-pituitary tumors or their treatment. Some experimental and clinical observations suggest that GH may possess a mitogenic potential, thus raising the question of whether it is a safe treatment in patients with a previous pituitary tumor. Few study results have been reported on this topic. All of them have inevitable methodological flaws that limit their conclusions. However, all studies report that replacement therapy with GH does not seem to increase the risk of tumor progression or recurrence, when compared to historical or matched controls. Considering the slow-growing nature of most of these benign tumors and the absence of conclusive evidence from the available studies, a continuous imaging surveillance and longer follow-up periods are nevertheless mandatory for a definite statement on the safety of GH treatment in patients with previous pituitary tumors.

AB - Most cases of adult GH deficiency (AGHD) result from hypothalamic-pituitary tumors or their treatment. Some experimental and clinical observations suggest that GH may possess a mitogenic potential, thus raising the question of whether it is a safe treatment in patients with a previous pituitary tumor. Few study results have been reported on this topic. All of them have inevitable methodological flaws that limit their conclusions. However, all studies report that replacement therapy with GH does not seem to increase the risk of tumor progression or recurrence, when compared to historical or matched controls. Considering the slow-growing nature of most of these benign tumors and the absence of conclusive evidence from the available studies, a continuous imaging surveillance and longer follow-up periods are nevertheless mandatory for a definite statement on the safety of GH treatment in patients with previous pituitary tumors.

UR - http://www.scopus.com/inward/record.url?scp=60749121262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60749121262&partnerID=8YFLogxK

M3 - Article

C2 - 19020392

AN - SCOPUS:60749121262

VL - 31

SP - 75

EP - 78

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 9 Suppl

ER -